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Received December 14, 2011; accepted June 6, 2012AbstractBackground: Sleep structure disruption and rapid eye movement (REM) sleep behavior disorders (RBD) have been previously reported in
patients with neurodegenerative diseases. However, similar studies have rarely been quantitatively conducted in type 3 spinocerebellar ataxia
(SCA3).
Methods: Fifteen patients with SCA3 and 16 healthy controls were recruited and evaluated by clinical history, International Cooperative Ataxia
Rating Scale (ICARS), Epworth sleepiness scale (ESS), and polysomnography.
Results: Patients with SCA3 had reductions in sleep efficiency and percentage of REM sleep, which were negatively correlated with the severity
of ataxia as evaluated by ICARS. REM sleep reduction occurred regardless of the presence of RBD, and severe reduction of REM sleep may
significantly disturb the assessment of RBD.
Conclusion: Poor sleep efficiency and REM sleep aberrations are the characteristics of sleep structure disruption in SCA3 as the disease
progresses. The incidence of respiratory disturbance during sleep or excessive daytime sleepiness was not significantly higher in SCA3 patients
than controls.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Cerebellar ataxias comprise many neurodegenerative
diseases, in which the autosomal dominant spinocerebellar
ataxias (SCA) usually have symptoms beginning at since
early- to mid-adulthood. Currently, there is still no remedy of
SCA. The most common SCA is type 3 (SCA3), followed by
types 1, 2, and 6. Each type of SCA is rare in general pop-
ulation.1 SCA3 is also known as Machado-Joseph disease; it* Corresponding author. Dr. Bing-Wen Soong, Department of Neurology,
National Yang-Ming University School of Medicine, 155, Section 2, Linong
Street, Taipei 112, Taiwan, ROC.
E-mail address: bwsoong@ym.edu.tw (B.-W. Soong).
1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.09.006is caused by an abnormal expansion of CAG trinucleotide
repeat in ATXN3 gene on chromosome 14q32.1,2 The CAG
repeat length is inversely correlated with the age at disease
onset. Clinically, SCA3 is characterized by progressive
cerebellar ataxia, ophthalmoplegia, pyramidal and extrapy-
ramidal dysfunctions and peripheral neuropathy. Neuro-
pathologic studies revealed a widespread neuronal
degeneration, including the dentate nucleus, spinocerebellar
tract, superior and middle cerebellar peduncles, medial
longitudinal fasciculus, vestibular and pontine nuclei, locus
coeruleus, red nuclei, globus pallidus, substantia nigra, sub-
thalamic nuclei, Clarke column, and spinal anterior horn
cells, with relatively preserved cerebellar Purkinje cells and
inferior olives.1,3e6hinese Medical Association. All rights reserved.
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SCA, including types 1, 2, 3, and 6.7 It is important to diag-
nose and treat sleep disturbances in patients with SCA in order
to improve the quality of life. In SCA3, many types of sleep
disturbances haven been reported, including periodic limb
movements during sleep (PLMS),8,9 rapid eye movement
(REM) sleep behavior disorder (RBD),8e12 restless leg
syndrome (RLS),8,10,13,14 excessive daytime sleepiness
(EDS),12 and obstructive sleep apnea (OSA).15 However, the
risk factors of these sleep disturbances in SCA3 are not yet
known. We proposed a hypothesis that the severity of ataxia
may predict the presence of sleep disturbances in SCA3. Thus,
15 patients with SCA3 and 16 healthy controls were recruited
and evaluated with ICARS, overnight audiovisual poly-
somnography (PSG) and questionnaires of daytime sleepiness
to quantitatively correlate ataxia with the features of sleep
disruption.
2. Methods2.1. ParticipantsThis study was approved by the Institutional Review Board
of Taipei Veterans General Hospital. After the written
informed consent was obtained, 15 consecutive patients with
SCA3, regardless of sleep complaints, including five women
and 10 men, age: 45.2  10.6 (mean  standard deviation)
years, range: 26e61 years, CAG repeat length in the expanded
alleles: 60e81, age at disease onset: 35.1  11.4 years, range:
16e53 years, duration of illness: 10.1  4.9 years, range:
5e20 years (Table 1), and 16 healthy controls, including nine
women and seven men, age 43.4  11.4 years, range, 24e57
years, were recruited into this study. Eight of the 15 patients
with SCA3 had the habit of regular hypnotics use. Three of
them quit using hypnotics three nights before the PSG
examination but the other five (patients 6, 7, 11, 12, 13) could
not sleep at all without taking hypnotics (Table 1). By contrast,Table 1
Patient demographics.
Patient
number/sex
CAG repeat Age at onset
of ataxia (yrs)
Disease
duration (yrs)
1/F 70 50 11
2/F 77 35 10
3/M 78 36 6
4/M 75 42 8
5/M 76 30 17
6/M 69 55 3
7/M 60 47 12
8/M 71 37 17
9/M 81 20 6
10/M 77 28 6
11/M 74 35 8
12/F 64 32 20
13/F 79 30 11
14/F 80 22 10
15/M 78 25 9
BMI ¼ body mass index; BP ¼ bupropion; CZ ¼ clonazepam; ESS ¼ Epworth
N/A ¼ not applicable; PT ¼ paroxetine; RBD ¼ REM sleep behavior disorder; Rnone of the controls had sleep complaints, chronic pulmonary,
neurologic, psychiatric or cardiovascular disease, history of
drug abuse, or taking hypnotics. The severity of ataxia was
rated by the International cerebellar ataxia rating scales
(ICARS), which is a semiquantitative 100-point scale “com-
partmentalized” into posture/stance, limb ataxia, dysarthria,
and oculomotor disability. It has been validated as a useful
clinical tool.162.2. Polysomnography recordingAll participants underwent all-night PSG with continuous
audiovisual recordings, including electroencephalography
(EEG: C3-A2, C4-A1, O1-A2), electro-oculography (EOG),
submental surface electromyography (EMG), nasal and oral
air flow, thoracic and abdominal respiratory movements, finger
oximetry, and electrocardiography. Sleep was staged accord-
ing to the standard criteria.17 Sleep onset latency was defined
as the time from lights off to the start of stage 1 sleep for
continual 3 epochs or other stages for 1 epoch. REM sleep
latency referred to the time from sleep onset to REM sleep
onset. Sleep efficiency was defined as the ratio of total sleep
time to time in bed. Arousals were scored following the Atlas
and Scoring Rules by the Atlas Task Force of the American
Sleep Disorders Association (1992). Respiratory events
referred to apnea and hypopnea. Apnea was defined as
cessation of breathing (decreased nasal or oral air flow to less
than 20% of baseline) for 10 seconds or longer, whereas
hypopnea denoted a decrease of nasal or oral air flow to 20%e
50% of baseline with 4% in oxyhemoglobin saturation.
Respiratory disturbance index (RDI) was defined as the
respiratory disturbance per hour of sleep. RDI  5 was defined
as having respiratory disturbance during sleep according to the
criteria proposed by American Academy of Sleep Medicine.18
On the day of PSG, ICARS was assessed and sleep history
regarding abnormal behaviors during sleep was obtained from
the patients, their bed partners or caregivers. The EpworthICARS BMI ESS Age at onset of
clinical RBD (yrs)
Prior
Medications
39 24.1 8 No RBD d
41 12.6 13 No RBD d
32 25.9 4 36 d
43 21.8 2 50 d
81 17.5 7 No RBD d
16 27.9 3 58 CZ/ZC/PT
57 N/A N/A 55 ZC/BP
6 25.3 1 50 d
33 18.9 5 25 d
22 21.8 3 No RBD d
69 21.5 4 No RBD CZ/ZD
53 23.4 9 No RBD RP/ST
56 18 5 36 ZD
29 22.9 11 No RBD d
66 21.6 4 28 d
sleepiness scale; ICARS ¼ International Cooperative Ataxia Rating Scale;
P ¼ risperidone; ST ¼ sertraline; ZC ¼ zopiclone; ZD ¼ zolpidem.
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daytime sleepiness. Excessive daytime sleepiness (EDS) was
defined as ESS  10.19
RBD was suspected on the basis of a long-standing history
of violent sleep behaviors and unpleasant dreams. PSG
evidence of intermittent increase of tonic and phasic EMG
activities during REM sleep was required to make the diag-
nosis definitive.20,21 PSG features of REM sleep without ato-
nia (RSWA) was defined according to the proposed criteria of
Lapierre and Montplasir.222.3. Statistical analysisPSG features were compared using the Wilcoxon rank sum
(Mann-Whitney) test. The clinical severity of ataxia, rated in
ICARS, was correlated with sleep efficiency, REM sleep
percentage, ESS, sleep onset latencies, sleep stage shifts, RDI,
REM sleep with phasic chin density, and RSWA period by
Spearman’s rank correlation. The proportions of participants
who had excessive daytime sleepiness (ESS  10) and respi-
ratory disturbance during sleep (RDI  5) were compared
between patients and controls by Fisher’s exact test. A p value
of less than 0.05 in the two-tailed tests was considered
significant. Multiple linear regression was not used to control
factors affecting sleep, such as age, sex, or disease duration,
because of the limited sample size and the use of nonpara-
metric statistical methods.
3. Results
By clinical history, RBD was reported in eight patients
(Table 1) but not in any of the controls by the time of PSG was
performed. Clinical RBD subsequently developed in three
more patients (one man and two women: patient 1, 2, 5) during
the 3-year follow-up after PSG. The mean age at onset of
clinical RBD was 42.3  12.6 years (range, 25e58 years),
which occurred 5.75  4.0 years after the onset of ataxia. OnlyTable 2
Sleep architecture observed in the patients with SCA3 in this study.
Patient
number/sex
Sleep
efficiency (%)
SWS (%) REM
sleep (%)
REM onset sleep
latency (min)
R
1/F 69.7 1.5 14.6 55.5 1
2/F 64.9 9.2 5.4 177.5 9
3/M 80.6 2.8 2.1 272.5 2
4/M 79.8 6.0 13.8 107.0 2
5/M 37.2 2.0 0 REM R
6/M 83.7 5.5 9.2 202.5 1
7/M 53.5 8.7 3.1 106.5 0
8/M 89.5 5.3 16.6 63 1
9/M 57.8 16.9 2.3 282.5 1
10/M 89.8 13.2 7.8 97 5
11/M 44.7 3.3 0 REM R
12/F 63.3 0 0 REM R
13/F 52 5.9 1.2 253 2
14/F 73 0 14.5 114 7
15/M 76.3 1 10.7 141 5
PSG ¼ polysomnography; RBD ¼ REM sleep behavior disorder; RDI ¼ resp
RSWA ¼ REM sleep without atonia; SWS ¼ stage III-IV slow wave sleep;  ¼four patients with RBD reported occasional unpleasant
dreams, including fighting with people or falling off cliffs.
While dreaming, seven patients with RBD fell off the bed. In
all the patients with RBD, the bed partners had witnessed
abnormal behaviors during sleep, such as hitting, kicking,
talking, or shouting. The PSG features of the patients with
SCA3 are summarized in Table 2. Although eight patients had
clinical RBD, neither vigorous movements on the EMG nor
sounds on microphone recording that mimicked speech was
observed in these patients during the single-night PSG
recording.
EDS (ESS  10) was observed in only two of the 15
patients (Table 1). Neither the average ESS nor the prevalence
of EDS was significantly different between the patients and
controls (Table 3). ESS did not correlate with ICARS, disease
duration or the expanded length of trinucleotide repeat.
Five of the 15 patients had respiratory disturbance during
sleep (RDI  5; Table 2). However, neither the average RDI
nor the prevalence of respiratory disturbance differed between
the patients and controls (Table 3).
Compared with healthy controls, patients with SCA3 had
a decrease in sleep efficiency and an increase in arousal index,
more sleep stage shifts, longer wake time after sleep onset and
stage I sleep, shorter stage II sleep, less REM sleep, longer
REM sleep onset latencies, as well as more RSWA and REM
sleep with phasic chin densities (Table 3). The sleep efficiency,
REM sleep percentage, REM sleep onset latency, and
percentage of RSWA and REM sleep with phasic chin densi-
ties were not statistically different between the patients with
RBD and those without (Table 4). REM sleep percentage was
either very short in some patients (only 2.1%, 2.3%, and 1.2%
of total sleep time in patients 3, 9 and 13, respectively; all of
them had RBD) or totally absent in others (patient 5, 11, 12;
Table 2).
The ICARS was found to be inversely correlated with sleep
efficiency (correlation coefficient: e0.786, p ¼ 0.001) and
REM sleep percentage (correlation coefficient: e0.595,SWA (%) REM sleep with
phasic chin density (%)
Clinical RBD
before PSG
RDI Age at
PSG (yrs)
1.21 14.99  0.8 61
.52 18.41  8.9 45
3.53 21.57 þ 24.0 42
0.13 25.97 þ 2.7 50
EM REM  0 47
2.04 10.88 þ 10.3 58
6.41 þ 0.2 59
.61 12.15 þ 2.3 54
9.61 19.61 þ 0 26
.29 12.70  6.4 34
EM REM  1.0 43
EM REM  11.8 52
5.0 23.33 þ 2.8 41
.6 11.23  0.2 32
.24 12.36 þ 0 34
iratory disturbance index (abnormal: 5), REM ¼ rapid eye movements;
absent; þ ¼ present.
Table 3
Comparison of sleep architecture between the patients with SCA3 and controls.
SCA3 (n ¼ 15) Controls (n ¼ 16) p
Age (yrs) 45.2  10.6 43.4  11.4 0.61
Total sleep time (min) 285.3  63.9 309.6  50.0 0.281
Sleep efficiency (%) 68.4  15.7 82.8  9.3 0.007
Arousal index 33.6  14.1 18.8  5.4 <0.001
Sleep onset latency (min) 29.7  35.8 21.9  21.1 0.808
Stage shifts 217.9  71.9 157.9  40.6 0.012
Wake time after sleep onset (min) 26.2  15.1 10.2  7.2 0.001
Stage I (%) 22.2  7.8 12.9  6.4 0.001
Stage II (%) 38.8  13.5 51.7  8.0 0.002
SWS: Stage III - IV (%) 5.4  4.9 8.8  8.1 0.286
REM sleep (%) 6.8  6.1 15.0  4.9 <0.001
REM sleep onset latency (min) 156.0  80.2 (n ¼ 12) 76.7  35.4 0.003
RSWA (%) 11.7  8.5 (n ¼ 12) 1.8  2.3 <0.001
REM sleep with phasic chin density (%) 15.8  5.9 (n ¼ 12) 5.8  4.3 <0.001
BMI 21.6  3.8 22.3  2.8 0.718
RDI 4.8  6.7 1.6  2.2 0.225
Incidence of respiratory disturbance 5/15 (33.3%) 2/16 (12.5%) 0.220
ESS 5.6  3.5 (n ¼ 14) 3.9  2.2 (n ¼ 14) 0.296
Prevalence of EDS 2/14 (14.3%) 0/14 (0%) 0.481
BMI ¼ body mass index; ESS ¼ Epworth sleepiness scale; EDS (excessive daytime sleepiness) ¼ ESS  10; RDI ¼ respiratory disturbance index (respiratory
disturbance: RDI  5); REM ¼ rapid eye movements; RSWA ¼ REM sleep without atonia; SWS ¼ stage III-IV slow wave sleep.
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and disease duration, however, did not correlate with any PSG
parameter.
4. Discussion
The patients with SCA3 apparently had lower sleep effi-
ciency and REM sleep structure disruption. Furthermore, the
severity of ataxia, measured with ICARS, seemed to be
inversely correlated with sleep efficiency and REM sleep
percentage, suggesting that they had more sleep disruption and
REM sleep disturbance as the disease progressed. To our
knowledge, this feature has never been reported before, and
the mechanism of sleep disruption in spinocerebellar ataxia
has rarely been discussed.
Poor sleep efficiency has been documented in Parkinson
disease,23,24 Alzheimer disease,23,25 and SCA2.26,27 In Par-
kinson disease, frequent awakening during sleep may be
attributed to bradykinesia and difficulty turning over in bed.
The shorter, shallower, and fragmented sleep in patients withTable 4
Comparison of the characteristics of REM sleep between SCA3 patients with RBD
Patients with RBD (n
Age (yrs) 45.5  11.8
Disease onset duration 9.5  4.8
ICARS 38.6  20.9
Trinucleotide repeat number 73.9  6.9
Sleep efficiency (%) 73.0  13.2
REM sleep (%) 7.4  6.0
REM sleep onset latency (min) 178.5  85.2
RSWA (%) 13.4  10.1
REM sleep with phasic chin density (%) 16.5  7.0
ICARS ¼ International Cooperative Ataxia Rating Scale; RBD ¼ REM sleep beh
atonia.
a No REM sleep during PSG in three of the seven patients without RBD.other neurodegenerative diseases, including SCA2 and
SCA3, may similarly stem from the same pathomechanism.
Besides bradykinesia, ataxia-related symptoms, such as
vertigo while turning on the bed and inadvertent and exces-
sive collision, might also play a significant role in their sleep
disturbance. In Parkinson disease, the reduction of REM
sleep duration was caused by the degeneration of dopami-
nergic nigrostriatal pathway with compensatory activation of
monoaminergic neurons in the brain stem.28 Reduced
concentration of dopaminergic transporter in the nigrostriatal
pathway has also been reported in SCA229 and SCA3.3,4
Therefore, it is conceivable that the REM sleep reduction
in Parkinson disease, SCA2 and SCA3 may have similar
pathomechanism.
EDS was reported in only few patients with SCA3 (Table
3), which might be due to a poor sleep efficiency and
OSA.12 EDS is frequently observed in patients with Parkinson
disease,30,31 and has been attributed to the use of anti-
parkinsonism medicines, i.e., dopaminergic agonists,32 which
are not prescribed to most patients with SCA3.and without.
¼ 8) Patients without RBD (n ¼ 7) p
44.8  10.0 0.981
10.9  5.2 0.590
47.7  21.3 0.613
74.0  5.4 0.757
63.2  17.6 0.397
6.0  6.6 0.533
111.0  50.7 (n ¼ 4a) 0.214
8.4  2.5 (n ¼ 4a) 0.570
14.3  3.1 (n ¼ 4a) 0.808
avior disorder; REM ¼ rapid eye movements; RSWA ¼ REM sleep without
Fig. 1. Correlation between ICARS and two polysomnographic parameters:
sleep efficiency (diamond) and REM sleep percentage (circle). ICARS ¼
International Cooperative Ataxia Rating Scale; REM ¼ rapid eye movements.
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RSWA and REM sleep phasic chin/legs densities significantly
increased in SCA3 with RBD, but not in SCA3 without
RBD.8,9 However, in this series, reduction in REM sleep
percentage and increase in REM sleep latency, percentage of
RSWA and REM sleep phasic chin densities were similarly
found in all patients with SCA3, regardless of the absence of
RBD (Table 4). The calculation of RSWA percentage might
have been less accurate in those patients who had very short
REM sleep. It may not be appropriate to compare RSWA or
REM sleep with phasic chin density percentage in patients
with extremely short REM sleep. Furthermore, four patients
without clinical RBD had no REM sleep at all during the
single-night PSG and therefore couldn’t be included in the
analysis of RSWA. Since the REM sleep duration seem to
diminish as the disease progresses, a patient with real RBD
may not be correctly diagnosed if REM sleep becomes absent
in advanced stage. A longitudinal study would be needed to
follow the clinical manifestation and PSG changes as the
disease evolves.
Snoring and sleep apnea have been reported in patients with
SCA3 in a questionnaire study.15 Several patients in our study
had respiratory disturbances recorded by PSG, but neither the
average RDI nor the incidence of respiratory disturbance was
significant higher than control. Therefore, the relationship
between sleep apnea and SCA3 was not corroborated in this
study based on PSG. Further studies in larger population may
be needed.
Because of the difficulty in recruitment and limited sample
size, only non-parametric statistical method could be used and
multivariate analysis could not be carried out to adjust con-
founding factors of sleep. Besides, the study group and
controls could not be perfectly matched in age and sex,
although the average age was not significantly different.
Furthermore, the PSG should have included anterior tibialis
EMG recording in most patients and controls, although it was
not a standard operating procedure in our sleep laboratory.
Medication effects to sleep could not be avoided in somepatients with their insistence of continuous use of hypnotics at
the time of PSG.
In conclusion, this genetic and polysomnographic study
provided evidence that, in SCA3, sleep efficiency and REM
sleep percentage inversely correlate with the progression of
ataxia symptom. REM sleep reduction occurs regardless of the
presence of RBD, which may have significant influence in
RBD assessment. Neither daytime sleepiness nor respiratory
disturbance during sleep is the feature of SCA3.
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